PDCD1 and skin squamous cell carcinoma: Additionally, two anti-programmed cell death 1 (anti-PD-1) antibodies, pembrolizumab and cemiplimab, have been approved for managing advanced CSCC when neither radiation nor surgery is a viable treatment option [11,12].